Natco Pharma Ltd - 524816 - Un Audited Financial Results For The Quarter Ended June 30, 2021 Under Regulation 33 Of SEBI (LODR) Regulations, 2015
Un Audited Financial Results for the quarter ended June 30, 2021 under Regulation 33 of SEBI (LODR) Regulations, 2015 Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
conference call invitation for NATCO Pharma Limited's Q1 FY22 results on Thursday, August 12, 2021 at 6 pm. Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO transfers Lenalidomide ANDA to Arrow NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Trading window of the company will be closed from 4th August 2021 and it will be opened on 16th August 2021 NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Approval Of The Unaudited Results And Consider Interim Dividend
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 ,inter alia, to consider and approve Approval of the Unaudited Results and consider interim Dividend Natco Pharma Ltd - 524816 - Clarification / Confirmation On News Item Appearing In 'Media / Publication'
With reference to the above subject, we wish to inform you that we had given a press release as 'legal update' on 7th July, 2021 We further clarify that the news article 'timesofindia.indiatimes.com' dated July 26, 2021 captioned 'HC restrains Natco Pharma from manufacturing, using insecticides with FMC Corporation''s patent' pertaining the press release made by the company on 7th July, 2021 NATCO PHARMA LTD. - 524816 - Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd with respect to news article appearing on https://timesofindia.indiatimes.com July 26, 2021 titled "HC restrains Natco from using insecticides with FMC Corp's patent".The reply is awaited. Natco Pharma Ltd - 524816 - Related Party Transaction For The FY 2020-21
Related Party Transaction for the FY 2020-21 Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q4 Investor presentation for the FY 2020-21
Biggest gainers & losers of the day: Paper, brokerage stocks fly high; Natco Pharma tanks 7%
Paper stocks and brokerage stocks have been on a roll today, with multiple counters hitting the buyer circuit. Multiple stocks fell after the stock exchanges sought clarification on them.